On or around 07/10/2017 (Other)
Filing Date: November 01, 2013
According to the law firm press release, the Complaint charges that defendants misrepresented the prospects for Food and Drug Administration (“FDA”) approval of Amarin’s Vascepa drug for the ANCHOR indication and failed to disclose that the FDA had informed Amarin that there was a lack of prospective, controlled clinical trial data demonstrating that pharmaceutical reduction of triglycerides significantly reduces residual cardiovascular risk.
On July 29, 2014, the Court issued an Order consolidating cases, appointing lead plaintiff, and also approving lead counsel. Lead Plaintiff filed a consolidated and amended complaint on September 19.
On April 26, 2016, the Court issued an Order granting Defendants' motion to dismiss without prejudice. Plaintiffs declined to amend their complaint, thus this case was dismissed with prejudice on May 24. A Notice of Appeal of this decision was filed on May 26. The Court of Appeals issued a Judgment affirming the District Court on May 23, 2017.
Company & Securities Information
Defendant: Amarin Corporation plc
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: AMRN
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Steven Sklar, et al. v. Amarin Corporation plc, et al.